Question

Indicate whether each of the following descriptions better applies to trastuzumab (T) which targets Her2, imatinib (I) which targets Bcr-Abl, or ipilimumab (P) which targets the CTLA4 protein.

( ) It is NOT an antibody.
( ) It counters the immunosuppressive microenvironment of tumors.
( ) It does not bind to a cancer cell component.

Answer 1

Imatinib is not an antibody and does not bind to a cancer cell component, while ipilimumab counters the immunosuppressive microenvironment of tumors. Trastuzumab is a monoclonal antibody targeting the HER2 receptor.

Step-by-step explanation:

The answer to the question 'Indicate whether each of the following descriptions better applies to trastuzumab (T) which targets Her2, imatinib (I) which targets Bcr-Abl, or ipilimumab (P) which targets the CTLA4 protein' is as follows:

• (I) It is NOT an antibody.
• (P) It counters the immunosuppressive microenvironment of tumors.
• (I) It does not bind to a cancer cell component.

Trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 receptor, which is overexpressed in some breast cancers. Imatinib is a small molecule inhibitor, not an antibody, that specifically targets Bcr-Abl, a fusion protein tyrosine kinase. Ipilimumab is also an antibody, but it targets CTLA-4, a protein involved in regulating the immune system, rather than directly targeting cancer cells or their components.